Oct 26, 2023 9:00am EDT Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial
Aug 31, 2023 9:00am EDT Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 10, 2023 4:15pm EDT Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Jun 27, 2023 9:00am EDT Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne
Jun 13, 2023 4:15pm EDT Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
Jun 08, 2023 9:00am EDT Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
May 26, 2023 4:00pm EDT Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
May 24, 2023 8:00am EDT Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
May 11, 2023 4:05pm EDT Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
Apr 20, 2023 6:00am EDT Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package
